Market Research Report
Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2018
|Published by||Global Markets Direct||Product code||484628|
|Published||Content info||33 Pages
Delivery time: 1-2 business days
|Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2018|
|Published: September 26, 2018||Content info: 33 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2018, provides an overview of the Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline landscape.
Pseudomonas aeruginosa has become an important cause of pneumonia. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system. Treatment includes antibiotics.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.